Related references
Note: Only part of the references are listed.Targeting DNA Damage Response and Replication Stress in Pancreatic Cancer
Stephan B. Dreyer et al.
GASTROENTEROLOGY (2021)
DNA damage repair as a target in pancreatic cancer: state-of-the-art and future perspectives
Lukas Perkhofer et al.
GUT (2021)
Preclinical models of pancreatic ductal adenocarcinoma: challenges and opportunities in the era of precision medicine
Yiqi Yu et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2021)
Interpreting Sequence Variation in PDAC-Predisposing Genes Using a Multi-Tier Annotation Approach Performed at the Gene, Patient, and Cohort Level
Michael T. Zimmermann et al.
FRONTIERS IN ONCOLOGY (2021)
Patient-derived tumor xenograft and organoid models established from resected pancreatic, duodenal and biliary cancers
Nhu-An Pham et al.
SCIENTIFIC REPORTS (2021)
The fidelity of cancer cells in PDX models: Characteristics, mechanism and clinical significance
Jiahao Shi et al.
INTERNATIONAL JOURNAL OF CANCER (2020)
Amplification of the Mutation-Carrying BRCA2 Allele Promotes RAD51 Loading and PARP Inhibitor Resistance in the Absence of Reversion Mutations
Pyoung Hwa Park et al.
MOLECULAR CANCER THERAPEUTICS (2020)
Differences between KC and KPC pancreatic ductal adenocarcinoma mice models, in terms of their modeling biology and their clinical relevance
Abakundanda Nsenga Ariston Gabriel et al.
PANCREATOLOGY (2020)
Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation
Eileen M. O'Reilly et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Upcoming Revolutionary Paths in Preclinical Modeling of Pancreatic Adenocarcinoma
Mirna Swayden et al.
FRONTIERS IN ONCOLOGY (2020)
Patient-Derived Xenograft Models of Pancreatic Cancer: Overview and Comparison with Other Types of Models
Patrick L. Garcia et al.
CANCERS (2020)
A Phase I/II Study of Veliparib (ABT-888) in Combination with 5-Fluorouracil and Oxaliplatin in Patients with Metastatic Pancreatic Cancer
Michael J. Pishvaian et al.
CLINICAL CANCER RESEARCH (2020)
Advances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation
Win Topatana et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma
Yunzhen Qian et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
Maintenance Therapy for ATM-Deficient Pancreatic Cancer by Multiple DNA Damage Response Interferences after Platinum-Based Chemotherapy
Elodie Roger et al.
CELLS (2020)
Targeting DNA Damage Response in Prostate and Breast Cancer
Antje M. Wengner et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
The mismatch repair-dependent DNA damage response: Mechanisms and implications
Dipika Gupta et al.
DNA REPAIR (2019)
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
Talia Golan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods
J. Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
DNA Oxidation and Excision Repair Pathways
Tae-Hee Lee et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Whole genomes define concordance of matched primary, xenograft, and organoid models of pancreas cancer
Deena M. A. Gendoo et al.
PLOS COMPUTATIONAL BIOLOGY (2019)
Pancreatic cancer organoids recapitulate disease and allow personalized drug screening
Else Driehuis et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
DNA damage repair deficiency as a predictive biomarker for FOLFIRINOX efficacy in metastatic pancreatic cancer
Sofia Palacio et al.
JOURNAL OF GASTROINTESTINAL ONCOLOGY (2019)
The contribution of DNA replication stress marked by high-intensity, pan-nuclear γH2AX staining to chemosensitization by CHK1 and WEE1 inhibitors
Leslie A. Parsels et al.
CELL CYCLE (2018)
Main steps in DNA double-strand break repair: an introduction to homologous recombination and related processes
Lepakshi Ranjha et al.
CHROMOSOMA (2018)
Recapitulating the clinical scenario of BRCA-associated pancreatic cancer in pre-clinical models
Talia Golan et al.
INTERNATIONAL JOURNAL OF CANCER (2018)
The ATR Inhibitor AZD6738 Synergizes with Gemcitabine In Vitro and In Vivo to Induce Pancreatic Ductal Adenocarcinoma Regression
Yann Wallez et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine
Andrew J. Aguirre et al.
CANCER DISCOVERY (2018)
Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer
Herve Tiriac et al.
CANCER DISCOVERY (2018)
Simultaneous Targeting of PARP1 and RAD52 Triggers Dual Synthetic Lethality in BRCA-Deficient Tumor Cells
Katherine Sullivan-Reed et al.
CELL REPORTS (2018)
Stratification of Pancreatic Ductal Adenocarcinomas Based on Tumor and Microenvironment Features
Francesco Puleo et al.
GASTROENTEROLOGY (2018)
Advanced pancreatic cancer: The standard of care and new opportunities
Amrallah A. Mohammad
ONCOLOGY REVIEWS (2018)
Germline and Somatic DNA Damage Repair Gene Mutations and Overall Survival in Metastatic Pancreatic Adenocarcinoma Patients Treated with FOLFIRINOX
Amikar Sehdev et al.
CLINICAL CANCER RESEARCH (2018)
Pancreas 3D Organoids: Current and Future Aspects as a Research Platform for Personalized Medicine in Pancreatic Cancer
Leticia Moreira et al.
CELLULAR AND MOLECULAR GASTROENTEROLOGY AND HEPATOLOGY (2018)
Modeling Therapy Resistance in BRCA1/2-Mutant Cancers
Amy Drean et al.
MOLECULAR CANCER THERAPEUTICS (2017)
The Inhibitory Effects of HYDAMTIQ, a Novel PARP Inhibitor, on Growth in Human Tumor Cell Lines With Defective DNA Damage Response Pathways
Enrico Mini et al.
ONCOLOGY RESEARCH (2017)
PARP inhibitors: Synthetic lethality in the clinic
Christopher J. Lord et al.
SCIENCE (2017)
AACR Project GENIE: Powering Precision Medicine through an International Consortium
Fabrice Andre et al.
CANCER DISCOVERY (2017)
Pancreatic cancer ascites xenograft-an expeditious model mirroring advanced therapeutic resistant disease
Talia Golan et al.
ONCOTARGET (2017)
Pancreatic Adenocarcinoma Therapeutic Targets Revealed by Tumor-Stroma Cross-Talk Analyses in Patient-Derived Xenografts
Remy Nicolle et al.
CELL REPORTS (2017)
ATM-deficiency increases genomic instability and metastatic potential in a mouse model of pancreatic cancer
Yiannis Drosos et al.
SCIENTIFIC REPORTS (2017)
ATM Deficiency Generating Genomic Instability Sensitizes Pancreatic Ductal Adenocarcinoma Cells to Therapy-Induced DNA Damage
Lukas Perkhofer et al.
CANCER RESEARCH (2017)
A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients
Berta Laquente et al.
BMC CANCER (2017)
Non-homologous end joining: advances and frontiers
Kai Yang et al.
ACTA BIOCHIMICA ET BIOPHYSICA SINICA (2016)
Genomic analyses identify molecular subtypes of pancreatic cancer
Peter Bailey et al.
NATURE (2016)
Epidemiology of pancreatic cancer
Milena Ilic et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2016)
Effects of Combined Treatment with Ionizing Radiation and the PARP Inhibitor Olaparib in BRCA Mutant and Wild Type Patient-Derived Pancreatic Cancer Xenografts
Ines Lohse et al.
PLOS ONE (2016)
WEE1 inhibition in pancreatic cancer cells is dependent on DNA repair status in a context dependent manner
Shruti Lal et al.
SCIENTIFIC REPORTS (2016)
Mechanisms of interstrand DNA crosslink repair and human disorders
Satoru Hashimoto et al.
GENES AND ENVIRONMENT (2016)
Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/metastatic pancreatic cancer
J. Bendell et al.
ANNALS OF ONCOLOGY (2015)
BRCA1 and BRCA2 mutations sensitize to chemotherapy in patient-derived pancreatic cancer xenografts
I. Lohse et al.
BRITISH JOURNAL OF CANCER (2015)
Increased in vitro and in vivo sensitivity of BRCA2-associated pancreatic cancer to the poly(ADP-ribose) polymerase-1/2 inhibitor BMN 673
Alexandra-Zoe Andrei et al.
CANCER LETTERS (2015)
GEMMs as preclinical models for testing pancreatic cancer therapies
Aarthi Gopinathan et al.
DISEASE MODELS & MECHANISMS (2015)
Whole genomes redefine the mutational landscape of pancreatic cancer
Nicola Waddell et al.
NATURE (2015)
Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma
Richard A. Moffitt et al.
NATURE GENETICS (2015)
Loss of ATM accelerates pancreatic cancer formation and epithelial-mesenchymal transition
Ronan Russell et al.
NATURE COMMUNICATIONS (2015)
Family history of cancer and the risk of cancer: a network of case-control studies
F. Turati et al.
ANNALS OF ONCOLOGY (2013)
Optimize radiochemotherapy in pancreatic cancer: PARP inhibitors a new therapeutic opportunity
Letizia Porcelli et al.
MOLECULAR ONCOLOGY (2013)
Signatures of mutational processes in human cancer
Ludmil B. Alexandrov et al.
NATURE (2013)
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Daniel D. Von Hoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Nucleotide Excision Repair in Eukaryotes
Orlando D. Schaerer
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2013)
The Pancreas Cancer Microenvironment
Christine Feig et al.
CLINICAL CANCER RESEARCH (2012)
Genetic susceptibility to pancreatic cancer
Alison P. Klein
MOLECULAR CARCINOGENESIS (2012)
Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation
E. Fokas et al.
CELL DEATH & DISEASE (2012)
Inactivation of Brca2 cooperates with Trp53R172H to induce invasive pancreatic ductal adenocarcinomas in mice A mouse model of familial pancreatic cancer
Georg Feldmann et al.
CANCER BIOLOGY & THERAPY (2011)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Inactivation of Brca2 Promotes Trp53-Associated but Inhibits KrasG12D-Dependent Pancreatic Cancer Development in Mice
Matthew Rowley et al.
GASTROENTEROLOGY (2011)
Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy
Eric A. Collisson et al.
NATURE MEDICINE (2011)
DNA Damage Response
Giuseppina Giglia-Mari et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2011)
DNA repair and synthetic lethality
Gong-she Guo et al.
INTERNATIONAL JOURNAL OF ORAL SCIENCE (2011)
DNA interstrand crosslink repair and cancer
Andrew J. Deans et al.
NATURE REVIEWS CANCER (2011)
Germline Brca2 Heterozygosity Promotes KrasG12D -Driven Carcinogenesis in a Murine Model of Familial Pancreatic Cancer
Ferdinandos Skoulidis et al.
CANCER CELL (2010)
Advanced pancreatic carcinoma: current treatment and future challenges
Anastasios Stathis et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2010)
Phenotype and Genotype of Pancreatic Cancer Cell Lines
Emily L. Deer et al.
PANCREAS (2010)
A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer
C. Yoo et al.
BRITISH JOURNAL OF CANCER (2009)
Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer
David O. Azorsa et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2009)
Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers
Wataru Sakai et al.
NATURE (2008)
The costs of using unauthenticated, over-passaged cell lines: how much more data do we need?
Peyton Hughes et al.
BIOTECHNIQUES (2007)
Validation of the 6th Edition AJCC Pancreatic Cancer Staging System - Report from the National Cancer Database
Karl Y. Bilimoria et al.
CANCER (2007)
Trp53R172H and KraSG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice
SR Hingorani et al.
CANCER CELL (2005)
Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse
SR Hingorani et al.
CANCER CELL (2003)
Establishment and characterization of four human pancreatic carcinoma cell lines -: Genetic alterations in the TGFBR2 gene but not in the MADH4 gene
JL Ku et al.
CELL AND TISSUE RESEARCH (2002)
Share Paper
